


Newsletter HIT-CF Europe


September 2018




HIT-CF Europe aims to evaluate the efficacy and safety of three drug candidates in patients with CF and rare mutations, pre-selected by their mini-intestines in the laboratory.




1 We take some tissue from the intestine



2 This tissue is cultured in the lab



3 The result is an organoid



4 On this organoid we test medicines



5 And we bring the correct medicines to the patients

Organoid screening study


The first part of the HIT-CF project aims at enrolling 500 people with CF with two rare CFTR-mutations from across Europe. A biopsy from these people will be taken and organoids will be generated.

In each European participating country separately, approval has to be obtained from the local Ethical Committee before the biopsy can be taken.

This month, recruiting will start in several countries!

- We have received approval for the study in: Czech Republic, Portugal, Spain, Belgium, Israel and the Netherlands!
- In the following countries we hope to get approval very soon: Poland, Sweden, Germany, France and Austria
- The other countries that are initializing the study are the following: United Kingdom, Italy and Denmark

More detailed information on the countries and hospitals that are participating can be found on www.hitcf.org



Testing organoids in different laboratories

All biopsies will be sent to HUB located in Utrecht, the Netherlands. HUB will generate organoids from biopsies and send the organoids to the organoid screening laboratories of University Medical Centre Utrecht, KU Leuven and Lisbon University.

Utrecht, Leuven, Lisbon and HUB have been working hard on preparing for the organoid screening phase, and we are confident we can start screening the first organoids in the months to come.

Do you want to participate, or do you want more info about the HIT-CF project?

Visit the website of HIT-CF or send an e-mail to HITCF@umcutrecht.nl



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 755021



Contact information

HIT-CF Europe, Joseph Borlélaan 12,
1160 Brussels, Belgium